FDA Clears Cepheid's TB Test | GenomeWeb

NEW YORK (GenomeWeb News) – Cepheid said after the close of the market on Thursday that its Xpert MTB/RIF test has received de novo 510(k) clearance from the US Food and Drug Administration for marketing in the US.

The test is available for immediate shipment in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.